Tactile Systems Technology

TCMD

Market cap $542M

MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system. The next-generation system maintains its indication for use as a treatment option for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis, across pediatric and geriatric populations, while introducing enhancements to patient comfort, ease of use, and connected care capabilities to support long-term therapy adherence.

MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the William Blair 46th Annual Growth Stock Conference, which is being held at the Loews Hotel in Chicago, IL, from June 2-4, 2026. Management will present on Tuesday, June 2, at 9:20 a.m. Central Time.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript

Tactile Systems Technology (TCMD) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.13 per share a year ago.

MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Summary and Recent Business Highlights: Total revenue increased 23% year-over-year to $75.3 million Gross margin of 76.5% versus 74% in Q1 2025 Net loss of $1.8 million versus $3.0 million in Q1 2025 Adjusted EBITDA of $3.7 million versus an Adjusted EBITDA loss of $0.3 million in Q1 2025 Expanded AI-enabled order management platform with the implementation of new operational capabilities to execute the Medicare prior authorization requirement for PCDs Repurchased $1.1 million of stock under the Company's share repurchase program Received FDA 510(k) clearance for next-generation AffloVest airway clearance device “We delivered a strong start to 2026, with first quarter revenue growth of 23% year-over-year driven by disciplined execution of our strategic priorities,” said Sheri Dodd, Chief Executive Officer of Tactile Medical.

MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2026 financial results will be released after the market closes on Monday, May 4, 2026.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

GMED, TCMD and IRMD tap GenAI to boost diagnostics and workflows, but high costs, regulation gaps and macro pressures still weigh on MedTech growth.

The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tactile Systems Technology (TCMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.